Krystal Biotech, Inc.

Krystal Biotech, Inc. is a commercial-stage biotechnology company that discovers, develops, manufactures, and commercializes genetic medicines for diseases with high unmet medical needs in the United States. Its lead commercial product is VYJUVEK (beremagene geperpavec-svdt, or B-VEC), approved for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. The company also has a pipeline of investigational therapies, including KB803 for ocular complications of DEB, KB801 for neurotrophic keratitis, KB407 for cystic fibrosis (Phase 1), KB111 for Hailey-Hailey disease, KB707 for solid tumors (Phase 1/2), KB304 for dynamic wrinkles, KB408 for Alpha-1 antitrypsin deficiency (Phase 1), and KB301 for aesthetic skin conditions (Phase 2). Krystal Biotech focuses on genetic medicine to address diseases with limited treatment options.

Krystal Biotech is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol KRYS. Its financial reporting and stock trading are conducted in US Dollars (USD). As a US-based company, its shares are traded in the United States, and the currency reflects the primary economic environment in which it operates.

Krystal Biotech operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing genetic medicines that modify or repair genes to treat diseases. Its work involves cutting-edge science, including gene therapy and viral vector technologies, to create treatments for conditions with high unmet medical needs, such as rare genetic disorders and certain cancers.

Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, United States. The company primarily serves the US market, as indicated by its description stating it commercializes genetic medicines in the United States. Its commercial product VYJUVEK is available in the US for dystrophic epidermolysis bullosa, and its clinical trials are likely conducted in the US. While the company may have global ambitions, its current operations and approved products are focused on the US.

Krystal Biotech generates revenue primarily through the commercialization of its approved product VYJUVEK (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). As a commercial-stage company, it sells this gene therapy to healthcare providers and patients. Additionally, the company may generate revenue from partnerships, collaborations, or licensing agreements for its pipeline candidates, though specific financial details are not provided. Its business model centers on developing and marketing genetic medicines for rare and serious diseases, with a focus on addressing high unmet medical needs.